



Zeal & Innovation in Medicine

Ref : ZLL/Compliance/LODR

Date : 24.11.2022

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
MUMBAI – 400 001
Company Code – 541400

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has organized a “Meet and Greet” event on the occasion of listing its shares on National Stock Exchange of India Limited (NSE). The analyst and the press/media will be participating in the event on 25th November, 2022 in Mumbai as per details given below:

| Day, Date | Details of Event/Meet | Venue | Type of Meeting |
|--|--|--------|-----------------|
| Friday, 25 th November, 2022 | “Meet and Greet” with Analyst and Press/ Media | Mumbai | Group meeting |

Please find attached herewith the presentation to be made during the event. The presentation is being uploaded simultaneously on the Company’s website (www.zimlab.in).

Kindly take the intimation on record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl : As above.

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960



ZIM LABORATORIES LIMITED

SAFE HARBOUR



The presentation has been prepared by ZIM Laboratories Limited (“ZIM” or the “Company”) solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions.

The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm.

Certain statements contained in this presentation may be statements of the Company's beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management's current expectations or beliefs as well as a number of assumptions about the Company's operations and factors beyond the Company's control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.



ZIM : A Brief Introduction

ZIM is a research driven pharmaceutical company that leverages on a range of technology based novel drug delivery solutions and non – infringing proprietary manufacturing processes to develop, manufacture and supply a wide range of innovative and differentiated generic pharmaceutical products


- ➊ Strong R&D expertise in complex generics and NDDS (Novel Drug Delivery Solution)
- ➋ Robust technology platforms capable to manufacture wide range of therapy- agnostic products
- ➌ Consistent and high quality supply of complex drugs
- ➍ Focused on improving patient convenience and adherence of drug treatment
- ➎ EU-GMP approved manufacturing facility

Technology Platforms

- **Micro-Emulsion Coating Technology (MECT)** : Used for solubilisation of oil soluble drug, liquids in oil phase and subsequently micro emulsifying with aqueous phase containing polymer to coat over the substrate.
- **Pellet Cold Forming Technology (PCFT)**: Used for heat sensitive material which either loses its potency or transform into another form at normal temperatures
- **Rapid Gelation Drug Release Technology (RGDRT)** : Used for release of drug in pseudo zero kinetics and is also an alternative to OROS technology
- **Matrix Pore Forming Tablet Technology (MAPOTAB)**: Used for release of drug through pores into an aqueous media



Manufacturing Process Capabilities



Stability Enhancement



Transmucosal Films Casting



Oral Films Casting



Taste Masking



Solvent Less Processing




Solubility Bioavailability Enhancement



Bi/Multi Layer Film Casting`



Active Nano Particulate Granulation



Multi Layered Pellets

Strong R&D Capabilities

Patents Granted - 9

| Dosage Form | Modified Drug Release | Solubility & Stability Enhancement | Dosage Transformation | Total |
|------------------|-----------------------|------------------------------------|-----------------------|-------|
| Pellets/Capsules | 24 | - | 2 | 26 |
| ODS | 2 | 12 | 14 | 28 |
| Tablets | 4 | - | - | 4 |
| Patent Filings | 30 | 12 | 16 | 58 |

Patents under examination - 45

Product Registrations -595

| Dosage Form | Registered | Applied | Pipeline | Total |
|------------------|------------|---------|----------|-------|
| Capsules/Tablets | 396 | 210 | 30 | 636 |
| Suspensions | 23 | 31 | - | 54 |
| ODS | 136 | 107 | 4 | 247 |
| Nutraceuticals | 40 | 48 | 6 | 94 |

Registrations in Pipeline - 436

State of the art Manufacturing units

ORAL DOSAGE (GENERAL) (EU GMP)

| | |
|----------------------------|---|
| Manufacturing Capabilities | Tablets, Capsules, DC Granules, Pellets and Dry Syrup |
| Accreditations | EU-GMP, ISO-9001 |

ORAL THIN FILM (EU GMP)

| | |
|----------------------------|----------------------------------|
| Manufacturing Capabilities | ORAL THIN FILM |
| Accreditations | EU-GMP, ISO-9001, NSF-ANSI 455-2 |



Our New Products

Products Ready to Out License

1. Acitretin Capsules 10mg/25mg
2. Dutasteride and Tamsulosin HCL capsules
0.5mg/0.4 mg
3. Pancreatin capsules 10000 IU/ 25000 IU

Products Undergoing BE and Other Clinical Studies

1. Dabigatran Etxilate capsules
75mg/110mg/150mg
2. Dimethyl Fumarate DR capsules 120/240 mg
3. Mirabegron PR Tablets 25 mg/50 mg
4. Tofacitinib Citrate PR tablets 11mg
5. Tofacitinib Citrate tablets 5mg/10mg

Oral Thin Films (OTF):

Thinoral[®], Mucostrip[®], Printoral[®], Spinoral[®], Sublingual, Bi-layer

- ZIM's R&D team has developed Oral Thin Films (OTF) which are manufactured using the company's in house Patented Thinoral[®] technology. ZIM manufactures pharmaceuticals and nutraceuticals on Oro dispersible, Sublingual and Buccal thin film technologies.
- Recently, ZIM received MAs for 2 of its ODS products: Rizatriptan Benzoate in Portugal and Sildenafil Citrate in Spain
- We have 7 patents granted and 14 under examination in OTF

3 OTF products registered in EU

12 OTF Pharmaceutical Products Developed


Products with CTD Dossier



1. Rizatriptan Benzoate ODS
2. Sildenafil Citrate ODS
3. Ondansetron ODS
4. Tadalafil ODS
5. Vitamin D3 ODS
6. Melatonin ODS



Partnership model



- ➊ Strategic R&D Partner to Global Companies
- ➋ Product Development, Manufacturing & Supply of PFI & Finished dosages
- ➌ Co-Development of New Products
- ➍ Out-Licensing of dossiers and Finished dosages supply
- ➎ Technology Transfer of Manufacturing processes
- ➏ Manufacturing of Complex Generics





Zeal & Innovation in Medicine

THANK YOU